Kaida BioPharma to Present at BioSparkVA Event

Kaida BioPharma, an emerging pharmaceutical company, has announced that its Chairman and Founder, Craig Pierson, will speak at the BioSparkVA's BioSpark Pitch Event. This event, organized by CVILLE Biohub and Cooley, is scheduled for today, September 26, 2024, in Charlottesville, Virginia. Kaida BioPharma is focused on developing advanced treatments for ovarian cancer through innovative drug solutions.

The company's primary project is KAD101, a novel biologic designed to inhibit the prolactin receptor, which is crucial for cancer cell growth. By blocking this receptor, KAD101 encourages autophagy, a process where cells break down their own components, thereby targeting ovarian cancer cells. In a recent clinical trial, KAD101 exhibited promising outcomes with all participating patients showing tumor reduction and maintaining a clean safety profile when administered as a daily injection. Kaida BioPharma is planning to initiate a Phase 1 study for KAD101 in 2025.

In addition to KAD101, Kaida BioPharma is working on KAD102. This new drug is an improved version of KAD101 and acts as a potent antagonist specifically designed for the treatment of uterine cancer.

Kaida BioPharma was founded on the research findings related to KAD101, formerly known as G129R. This growth hormone antagonist has been proven to trigger autophagy in gynecologic tumors. The company's foundation is built on collaborative research with experts like Dr. John Langenheim from Thomas Jefferson University and Dr. Anil Sood from MD Anderson, who have extensively studied G129R. These collaborations have been instrumental in bringing forward potential solutions for clinical use.

The mission of Kaida BioPharma is to offer hope to patients dealing with treatment-resistant gynecological cancers. The company is committed to developing innovative therapies that cater specifically to the needs of these patients, aiming to make a significant impact on their lives.